Overview

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)

Status:
Active, not recruiting

Trial end date:
2024-07-29

Target enrollment:

Participant gender:

Summary

This study will examine the effects of predefined 2 week duvelisib dose holidays on tumor responses and safety/tolerability.

Phase:

Phase 2

Details

Lead Sponsor:

SecuraBio
Verastem, Inc.